BridgeBio Pharma, Inc.
BBIONASDAQHealthcare● Active
$67.61
+$0.28(+0.42%)
Market Cap$13.2B
P/E Ratio—
52W High$84.94
52W Low$37.69
BridgeBio Pharma, Inc.（BBIO）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · BBIO · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.50B | $0.22B | $0.01B | $0.08B | $0.07B |
| Cost of Revenue | $0.03B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.47B | $0.22B | $0.01B | $0.07B | $0.07B |
| Gross Margin %(computed) | 94.37% | 98.25% | 73.71% | 95.58% | 95.53% |
| Operating Expenses | |||||
| R&D Expenses | $0.48B | $0.51B | $0.46B | $0.40B | $0.45B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $1.04B | $0.81B | $0.61B | $0.59B | $0.64B |
| Operating Income | ($0.57B) | ($0.59B) | ($0.61B) | ($0.51B) | ($0.58B) |
| Operating Margin %(computed) | -113.35% | -267.22% | — | -659.65% | -827.12% |
| Interest Income | $0.02B | $0.02B | $0.02B | $0.01B | $0.00B |
| Interest Expense | $0.05B | $0.10B | $0.08B | $0.08B | $0.05B |
| Income Before Tax | ($0.73B) | ($0.54B) | ($0.65B) | ($0.48B) | ($0.59B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.73B) | ($0.54B) | ($0.64B) | ($0.48B) | ($0.56B) |
| Net Margin %(computed) | -145.26% | -241.44% | — | -619.70% | -806.90% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.79 | $-2.88 | $-3.95 | $-3.35 | $-3.90 |
| Wtd Avg Shares | 0.20B | 0.19B | 0.16B | 0.15B | 0.14B |
| EBITDA | ($0.67B) | ($0.44B) | ($0.57B) | ($0.40B) | ($0.53B) |
| EBITDA Margin %(computed) | -134.02% | -196.86% | — | -511.85% | -765.73% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-08 · USD · B
深入了解BridgeBio Pharma, Inc.
关于BridgeBio Pharma, Inc.（BBIO）损益表
BridgeBio Pharma, Inc.（BBIO）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，BBIO实现营收$0.50B，毛利润$0.47B（毛利率94.37%），净利润($0.73B)（净利率-145.26%）。
常见问题
BBIO · 4 问BridgeBio Pharma, Inc.（BBIO）2025财年营收为$0.50B，同比up126.3%。
BBIO revenueBBIO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08